BRAF and colorectal carcinoma: Moreover, studies have shown that anti-EGFRs are the recommended first-line targeted treatment for left-sided RAS/BRAF WT CRC, as evidenced by the numerically longer PFS, greater ORR, and statistically significantly longer OS [54].